Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of AS-1763 in healthy adults
NL-OMON51167Phase 1Completed
- Sponsor
- Carna Biosciences, Inc.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of docirbrutinib in B-cell chronic lymphocytic leukemia (B-CLL), mature B-cell lymphoma, Inflammatory Disorders and 2 more (3 arms), sponsored by Carna Biosciences, Inc. Primary endpoint: Safety and tolerability. Started Mar 2021; status: completed.
02
Drugs
docirbrutinib
03
Conditions
B-cell chronic lymphocytic leukemia (B-CLL)mature B-cell lymphomaInflammatory Disordersrheumatoid arthritis (RA)autoimmune disease
Beyond the preview
Go deeper on NL-OMON51167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51167.